Capital Economics: Risks Facing the Indian Economy Go Beyond Oil

金十2026/03/06 10:53

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to Golden Ten Data on March 6, Shilan Shah from Capital Economics wrote in a report that, as the United States temporarily eased sanctions on Russian oil purchases to alleviate price pressures, India has gained some breathing space. However, the economist pointed out that other factors, such as the surge in liquefied natural gas prices caused by production halts in Qatar, may force the government to increase fertilizer subsidies. Last year, the total amount of fertilizer subsidies was about $20 billion. Liquefied natural gas is used as a raw material for domestic fertilizer plants in India. Shah added that prolonged conflicts in the Middle East could also lead to a reduction in remittances from Gulf economies, which account for about one-third of India's total remittances. Remittances remain an important source of external funding for the Indian economy.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)

路透社•2026/10/08 16:11